Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 4,864 shares at $101.05 ($472K) on 2018-02-13, disclosed to the SEC on 2018-02-14.
Open-market sale of $472k LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $92.21 | 500 | $46K | 9.8% |
| 2 | $93.83 | 741 | $70K | 14.7% |
| 3 | $93.83 | 741 | $70K | 14.7% |
| 4 | $94.49 | 300 | $28K | 6.0% |
| 5 | $94.33 | 300 | $28K | 6.0% |
| 6 | $96.60 | 100 |
| $10K |
| 2.0% |
| 7 | $97.87 | 100 | $10K | 2.1% |
| 8 | $101.05 | 1,041 | $105K | 22.3% |
| 9 | $101.05 | 1,041 | $105K | 22.3% |
| Total | $96.97 avg | 4,864 | $472K | 100% |
| Filing → |
| LOXO | SELL | 2018-11-28 | $1.5M | — | Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |